Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Neuroendocrine Tumors

Disease Attributes

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Antineoplastic Agents

Gastrointestinal Agents

Somatostatin

Octreotide

Antineoplastic Agents, Hormonal

Patients will receive 6-12 monthly injections every 28 (+/- 3) days.

Chuyan Chen, MD

Jingnan Li, MD

This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type I gastric neuroendocrine tumors.

Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

An Observational Study Investigating Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

Measured by a questionnaire, including whether the patient presents with dyspepsia, abdominal pain, cramps, bloating, nausea, vomiting, lack of appetite, facial flushing.

Concentration of serum Gastrin after 12 hours of fasting

Normal Hyperplasia: ECL cell proliferation with a diameter \<150 μm, distinguished in: normal pattern/simple hyperplasia, linear, micronodular and adenomatoid hyperplasia.

Dysplasia: ECL cell proliferation \>150 but \<500 μm. Type I gastric carcinoid: ECL proliferation \>500 μm.

Measured by a questionnaire for patients and clinician's report. Including: hypersensitivity, endocrine disorders (abnormal thyroid functions), metabolism and nutrition disorders (abnormal blood glucose), headache, bradycardia or tachycardia, dyspnea, gastrointestinal disorders (diarrhea, abdominal pain, nausea, constipation, flatulence), hepatobiliary disorders, skin disorders, injection site reaction.

Peking Union Medical College Hospital

Head of Gastroenterology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs	NCT03812939	Gastric NET	Octreotide	18 Years - 80 Years	Peking Union Medical College Hospital
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs	NCT03812939	Gastric NET	Octreotide	18 Years - 80 Years	Peking Union Medical College Hospital
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs	NCT03812939	Gastric NET	Octreotide	18 Years - 80 Years	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for gastric net

Every month we try and update this database with for gastric net cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for gastric net

Every month we try and update this database with for gastric net cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for gastric net cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.